Tezepelumab is an epithelial cytokine blocker used to treat severe asthma; its efficacy and safety in patients with chronic rhinosinusitis with nasal polyps have been unclear. New research ...

Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...

The following is a summary of “Shared genetic investigation of asthma and blood eosinophils in relation to chronic rhinosinusitis,” published in the March 2025 issue of Allergy, Asthma & Clinical ...

Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...

The same was true for IL-8. SAN DIEGO — Among patients with chronic rhinosinusitis, higher IL-6 and IL-8 levels had links to decreases in several cognitive function domains including episodic ...

Tezepelumab reduced the size of nasal polyps and the severity of nasal congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, in a placebo-controlled study.

A new study published in the European Archives of Oto-Rhino-Laryngology revealed that serum 25(OH)D deficiency is an ...

Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update. Rapid de ...